

Introducing a Novel Personalized Microbiome-Based Treatment for Inflammatory Bowel Disease

Biomedicines (MDPI), 2025
<https://www.mdpi.com/2227-9059/13/4/795>

Design	Prospective interventional internal validation study. No randomised control arm.
Intervention	AI-driven personalized microbiome modulation (PMM).
Reported outcome	Improvement in symptom control and remission rates.
Statistics	Effect sizes, confidence intervals and p-values as reported in the publication.

Scope of this document

This is a one-page orientation to the study design and reported outcomes. It is not a substitute for the publication. Full eligibility criteria, endpoint definitions, assay methods, statistical analysis, confidence intervals, ethics approval, funding and declared conflicts of interest are given in the peer-reviewed paper linked above.

Limitations that apply to this study

The study is not a randomised controlled trial. Without a control arm, placebo response, regression to the mean and selection effects cannot be separated from the intervention effect. Patient-reported outcomes are subjective. Results describe the population studied and should not be extrapolated beyond it.

Requests for analysis-level data or a protocol review: research@nostrabiome.ai
Methodology questions are answered at nostrabiome.ai/research-faq